
Enzalutamide Plus Leuprolide Extends Survival in High-Risk Non-Metastatic Prostate Cancer
Pfizer and Astellas have released topline results from the phase 3 EMBARK trial, demonstrating that enzalutamide (Xtandi; Pfizer, Astellas) combined with leuprolide significantly improves overall survival (OS) and confirms previous metastasis-free survival …